Arthritis & rheumatology (Hoboken, N.J.) · 2026
The Role of IgM Anti-acetylated Protein Antibodies and B Cells in the Origin of Antimodified Protein Autoimmunity in Rheumatoid Arthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Athanasiadou Aegli, Kroos Sanne, van de Wetering Renee, Schopmeijer Rian, van der Keur Carin, Eikmans Michael, Meijer Caroline, Rantapää-Dahlqvist Solbritt, Toes René E M, Slot Linda M, van der Woude Diane
Аннотация
OBJECTIVE: Rheumatoid arthritis (RA) is characterized by anti-modified protein antibodies (AMPAs), including anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP), and anti-acetylated protein antibodies (AAPA). In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role in early immune responses. We investigated whether AAPA IgM serves as a precursor for other AMPAs, marking the initial breach of tolerance in RA.
METHODS: AAPA IgM levels were measured in cord blood and serum of children up to three years old to assess whether it represents a natural (auto)antibody. To evaluate whether AAPA IgM presence precedes other AMPAs, we longitudinally measured AAPA and ACPA IgM in individuals before RA onset. To assess whether AAPA IgM-expressing B cells display a naive phenotype and carry germline-encoded B cell receptors (BCRs), single cells were sorted and sequenced.
RESULTS: AAPA IgM was not detected in early life, but before RA onset, significantly more individuals were AAPA IgM positive (27.3%) compared to ACPA IgM positive (11.7%). Toward disease onset, ACPA IgM positivity increased to 51.2%, whereas AAPA IgM positivity remained stable. Furthermore, AMPAs developed in individuals who were AAPA IgM negative. Regarding B cell characteristics, germline-encoded BCRs were identified among both AAPA- and ACPA-expressing B cells in patients with RA.
CONCLUSION: AMPA responses in RA do not appear to arise solely from AAPA IgM, as suggested by the lack of association between predisease AMPA IgM positivity and later AMPA evolution. This is further supported by the presence of germline-configured ACPA BCRs, suggesting multiple possible starting points for AMPA responses.
METHODS: AAPA IgM levels were measured in cord blood and serum of children up to three years old to assess whether it represents a natural (auto)antibody. To evaluate whether AAPA IgM presence precedes other AMPAs, we longitudinally measured AAPA and ACPA IgM in individuals before RA onset. To assess whether AAPA IgM-expressing B cells display a naive phenotype and carry germline-encoded B cell receptors (BCRs), single cells were sorted and sequenced.
RESULTS: AAPA IgM was not detected in early life, but before RA onset, significantly more individuals were AAPA IgM positive (27.3%) compared to ACPA IgM positive (11.7%). Toward disease onset, ACPA IgM positivity increased to 51.2%, whereas AAPA IgM positivity remained stable. Furthermore, AMPAs developed in individuals who were AAPA IgM negative. Regarding B cell characteristics, germline-encoded BCRs were identified among both AAPA- and ACPA-expressing B cells in patients with RA.
CONCLUSION: AMPA responses in RA do not appear to arise solely from AAPA IgM, as suggested by the lack of association between predisease AMPA IgM positivity and later AMPA evolution. This is further supported by the presence of germline-configured ACPA BCRs, suggesting multiple possible starting points for AMPA responses.